Synthetic Human FANCL blocking peptide for Apuri, BL, ELISA
Blocking/Immunizing peptide for anti-FANCL antibody
Human, Mouse, Cow, Dog, Rat
For in vitro research use only. Not intended for any diagnostic or therapeutic purpose. Not for human or animal consumption.
Shipped at ambient temperature, store at -20°C.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms.
ligase activity; metal ion binding; ubiquitin-protein ligase activity; ubiquitin-protein ligase activity; zinc ion binding;
FANCL; Fanconi anemia, complementation group L; PHD finger protein 9 , PHF9; E3 ubiquitin-protein ligase FANCL; FAAP43; FLJ10335; Pog; PHD finger protein 9; fanconi anemia group L protein; fanconi anemia-associated polypeptide of 43 kDa; POG; PHF9;